Proprietary AI analyst is now available
- Public Comps
- Boston Scientific
Boston Scientific Valuation Multiples
Discover Boston Scientific's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Edwards Lifesciences, IDEXX Laboratories, Siemens Healthineers, Agilent and more.
Boston Scientific Overview
About Boston Scientific
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
Founded
1979
HQ

Employees
59.0K
Website
Financials (LTM)
EV
$77B
Valuation Multiples
Start free trialBoston Scientific Financials
Boston Scientific reported last 12-month revenue of $21B and EBITDA of $6B.
In the same LTM period, Boston Scientific generated $15B in gross profit, $6B in EBITDA, and $5B in net income.
Revenue (LTM)
Boston Scientific P&L
In the most recent fiscal year, Boston Scientific reported revenue of $20B and EBITDA of $6B.
Boston Scientific is profitable as of last fiscal year, with gross margin of 69%, EBITDA margin of 31%, and net margin of 23%.
Financial data powered by Morningstar, Inc.
Boston Scientific Stock Performance
Boston Scientific has current market cap of $67B, and enterprise value of $77B.
Market Cap Evolution
Boston Scientific's stock price is $45.29.
Boston Scientific share price decreased by 6.3% in the last 30 days, and by 57.8% in the last year.
Boston Scientific has an EPS (earnings per share) of $3.08.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $77B | $67B | 0.0% | -6.3% | -27.8% | -57.8% | $3.08 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBoston Scientific Valuation Multiples
Boston Scientific trades at 3.7x EV/Revenue multiple, and 11.8x EV/EBITDA.
EV / Revenue (LTM)
Boston Scientific Financial Valuation Multiples
As of June 21, 2026, Boston Scientific has market cap of $67B and EV of $77B.
Boston Scientific has a P/E ratio of 14.1x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Boston Scientific Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Boston Scientific Margins & Growth Rates
Boston Scientific grew revenue by 8% and EBITDA by 9% in the last fiscal year.
In the most recent fiscal year, Boston Scientific reported gross margin of 69%, EBITDA margin of 31%, and net margin of 23%.
Boston Scientific Margins
Boston Scientific Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Boston Scientific Operational KPIs
Boston Scientific's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Boston Scientific's Rule of 40 is 39% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Boston Scientific's Rule of X is 51% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Boston Scientific Competitors
Boston Scientific competitors include Edwards Lifesciences, IDEXX Laboratories, Siemens Healthineers, Agilent, Waters, Medtronic, Alcon, GE HealthCare, DexCom and Stryker.
Most Boston Scientific public comparables operate across Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 7.8x | 7.4x | 26.1x | 24.2x | |||
| 10.5x | 10.1x | 30.0x | 28.4x | |||
| 1.6x | 1.6x | 7.8x | 8.0x | |||
| 5.4x | 5.2x | 18.7x | 17.7x | |||
| 12.6x | 8.5x | 35.4x | 25.4x | |||
| 3.3x | 3.3x | 12.0x | 11.8x | |||
| 3.4x | 3.4x | 13.2x | 13.1x | |||
| 1.8x | 1.7x | 9.6x | 9.7x | |||
This data is available for Pro users. Sign up to see all Boston Scientific competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by Boston Scientific
Boston Scientific has acquired 42 companies to date.
Last acquisition by Boston Scientific was on January 15th 2026. Boston Scientific acquired Penumbra for $15B (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Boston Scientific
| Description | Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases. | Valencia Technologies is a medical device company developing neuromodulation therapies for overactive bladder. Nashville-headquartered, it commercializes the eCoin peripheral tibial nerve stimulator, FDA-approved in 2022 for urge urinary incontinence. The coin-sized implant delivers six months of automated stimulation without batteries, wires, or recharging, via a 20-minute office procedure under local anesthesia. Over 1,000 patients treated show sustained symptom relief at 36 months, with coverage by Medicare and major insurers. | Nalu Medical is a Carlsbad-headquartered medtech company offering implantable neurostimulation systems for chronic pain relief via spinal cord stimulation and peripheral nerve stimulation. Its micro-IPG features a battery-free design powered by an external Therapy Disc, with FDA clearances for both indications, smartphone app control, and software waveforms. A compact Therapy Disc version enhances comfort for peripheral applications. | - | |
| HQ Country | |||||
| HQ City | San Francisco, CA | - | San Diego, CA | - | |
| Deal Date | 15 Jan 2026 | 12 Jan 2026 | 17 Oct 2025 | 9 Sep 2025 | |
| Valuation | $15B | undisclosed | $533M | $88M | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Boston Scientific acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Investments by Boston Scientific
Boston Scientific has invested in 20 companies to date.
Latest investment by Boston Scientific was on May 17th 2026. Boston Scientific invested in MiRus in their $2B Strategic investment round (EV/Revenue multiple available to Pro users).
Latest Investments by Boston Scientific
| Description | MiRus is a medical device company developing bioabsorbable implants for spine and orthopedics. Its Freedom LYRA system, launched in 2023, uses magnesium alloy screws that dissolve over 12-18 months, implanted in 500 cervical fusion surgeries across US centers. | 4C Medical Technologies is a medical device company developing transcatheter mitral valve replacement systems for structural heart disease. Minneapolis-based, its Altis device anchors in the left atrium to preserve native valve anatomy and ventricular function. Incorporated in 2015, the firm has completed first-in-human implants in Europe and holds FDA Breakthrough Device Designation. | Nectero Medical is a Dover, Delaware-headquartered developer of endovascular therapies for cardiovascular diseases. Its lead product, the Nectero EAST system, delivers a one-time infusion to halt progression and stabilize small to mid-sized abdominal aortic aneurysms measuring 3.5 to 5.0 centimeters. Founded in 2017, the company completed Phase I/IIa trials in 2023 with positive safety data from 30 patients and holds FDA Breakthrough Device Designation for accelerated review. | Nectero Medical is a Dover, Delaware-headquartered developer of endovascular therapies for cardiovascular diseases. Its lead product, the Nectero EAST system, delivers a one-time infusion to halt progression and stabilize small to mid-sized abdominal aortic aneurysms measuring 3.5 to 5.0 centimeters. Founded in 2017, the company completed Phase I/IIa trials in 2023 with positive safety data from 30 patients and holds FDA Breakthrough Device Designation for accelerated review. | |
| HQ Country | |||||
| HQ City | Atlanta, GA | - | Tempe, AZ | Tempe, AZ | |
| Deal Date | 17 May 2026 | 5 Mar 2025 | 11 Apr 2024 | 10 Sep 2021 | |
| Round | Strategic investment | Series D | Series D | Series C | |
| Raised | $2B | $175M | $96M | $20M | |
| Investors | Boston Scientific | Boston Scientific; Fu Yuan Investment | Alumni Ventures; Aphelion Capital; BioStar Capital; Boston Scientific; Cadence Healthcare Ventures; Norwest | Boston Scientific; KOFA Healthcare | |
| Valuation | $4B | undisclosed | undisclosed | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Boston Scientific investments and their VC round multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Boston Scientific
| When was Boston Scientific founded? | Boston Scientific was founded in 1979. |
| Where is Boston Scientific headquartered? | Boston Scientific is headquartered in United States. |
| How many employees does Boston Scientific have? | As of today, Boston Scientific has over 59K employees. |
| Who is the CEO of Boston Scientific? | Boston Scientific's CEO is Michael F. Mahoney. |
| Is Boston Scientific publicly listed? | Yes, Boston Scientific is a public company listed on NYSE. |
| What is the stock symbol of Boston Scientific? | Boston Scientific trades under BSX ticker. |
| When did Boston Scientific go public? | Boston Scientific went public in 1992. |
| Who are competitors of Boston Scientific? | Boston Scientific main competitors include Edwards Lifesciences, IDEXX Laboratories, Siemens Healthineers, Agilent, Waters, Medtronic, Alcon, GE HealthCare, DexCom, Stryker. |
| What is the current market cap of Boston Scientific? | Boston Scientific's current market cap is $67B. |
| What is the current revenue of Boston Scientific? | Boston Scientific's last 12 months revenue is $21B. |
| What is the current revenue growth of Boston Scientific? | Boston Scientific revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Boston Scientific? | Current revenue multiple of Boston Scientific is 3.7x. |
| What is the current EBITDA of Boston Scientific? | Boston Scientific's last 12 months EBITDA is $6B. |
| What is Boston Scientific's EBITDA margin? | Boston Scientific's last 12 months EBITDA margin is 31%. |
| What is the current EV/EBITDA multiple of Boston Scientific? | Current EBITDA multiple of Boston Scientific is 11.8x. |
| What is the current FCF of Boston Scientific? | Boston Scientific's last 12 months FCF is $4B. |
| What is Boston Scientific's FCF margin? | Boston Scientific's last 12 months FCF margin is 18%. |
| What is the current EV/FCF multiple of Boston Scientific? | Current FCF multiple of Boston Scientific is 20.4x. |
| How many companies Boston Scientific has acquired to date? | As of June 2026, Boston Scientific has acquired 42 companies. |
| What was the largest acquisition by Boston Scientific? | $15B acquisition of Penumbra on 15th January 2026 was the largest M&A Boston Scientific has done to date. |
| What companies Boston Scientific acquired? | Boston Scientific acquired Penumbra, BTG International, Axonics Modulation Technologies, Baylis Medical Company, American Medical Systems, Preventice Solutions, Silk Road Medical, LUMENIS (surgical unit), Relievant Medsystems, Acotec Scientific Hldgs, and 32 other companies. |
| In how many companies Boston Scientific has invested to date? | As of June 2026, Boston Scientific has invested in 20 companies. |
| What was the last Boston Scientific investment? | On 17th May 2026 Boston Scientific invested in MiRus, participating in a $2B Strategic investment round at $4B valuation. |
| In what companies Boston Scientific invested in? | Boston Scientific invested in MiRus, 4C Medical Technologies, Preventice Solutions, Nectero Medical, Saluda Medical, Pulmonx, NxThera, Amphora Medical, SetPoint Medical, BAROnova, NeuroTronik, Channel Medsystems, Sensible Medical Innovations, Neuros Medical, InterVene, TVA Medical, Securus Medical Group, RenovoRx, Append Medical, and Millipede. |
See public comps similar to Boston Scientific
Lists including Boston Scientific
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
